Analysts Set Perrigo Company plc (NYSE:PRGO) Price Target at $19.33

Shares of Perrigo Company plc (NYSE:PRGO) have been assigned an average rating of “Hold” from the six analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $19.3333.

Several equities research analysts recently issued reports on the stock. Canaccord Genuity Group decreased their target price on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. Wall Street Zen downgraded shares of Perrigo from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reissued a “sell (d+)” rating on shares of Perrigo in a research note on Monday, December 22nd. JPMorgan Chase & Co. cut their target price on Perrigo from $20.00 to $18.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Finally, Jefferies Financial Group reiterated a “hold” rating on shares of Perrigo in a report on Thursday, February 26th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Fuller & Thaler Asset Management Inc. increased its position in shares of Perrigo by 291.9% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 7,824,759 shares of the company’s stock worth $108,921,000 after acquiring an additional 5,828,076 shares in the last quarter. Norges Bank purchased a new stake in Perrigo during the 4th quarter worth $42,607,000. Invesco Ltd. increased its holdings in Perrigo by 134.2% in the 4th quarter. Invesco Ltd. now owns 4,542,415 shares of the company’s stock valued at $63,230,000 after purchasing an additional 2,602,724 shares in the last quarter. ION Fund Management Ltd purchased a new position in Perrigo in the fourth quarter valued at about $24,499,000. Finally, Perpetual Ltd lifted its stake in shares of Perrigo by 64.2% during the third quarter. Perpetual Ltd now owns 3,149,878 shares of the company’s stock worth $70,148,000 after purchasing an additional 1,231,400 shares in the last quarter. Hedge funds and other institutional investors own 95.91% of the company’s stock.

Perrigo Stock Performance

Shares of PRGO opened at $11.70 on Monday. Perrigo has a 1 year low of $11.30 and a 1 year high of $29.55. The company’s 50 day simple moving average is $14.30 and its 200 day simple moving average is $17.21. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of -1.14, a PEG ratio of 1.37 and a beta of 0.41. The company has a debt-to-equity ratio of 1.23, a quick ratio of 1.63 and a current ratio of 2.76.

Perrigo (NYSE:PRGO) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.77 earnings per share for the quarter, missing analysts’ consensus estimates of $0.80 by ($0.03). Perrigo had a positive return on equity of 9.41% and a negative net margin of 33.51%.The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the prior year, the company earned $0.93 EPS. The company’s revenue for the quarter was down 2.5% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, sell-side analysts predict that Perrigo will post 2.56 EPS for the current year.

Perrigo Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 24th. Stockholders of record on Monday, March 2nd will be issued a dividend of $0.29 per share. The ex-dividend date is Monday, March 2nd. This represents a $1.16 dividend on an annualized basis and a dividend yield of 9.9%. Perrigo’s payout ratio is presently -11.28%.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.